Format
Items per page
Sort by

Send to:

Choose Destination

Results: 11

1.

Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair.

Alli E, Solow-Cordero D, Casey SC, Ford JM.

Cancer Res. 2014 Nov 1;74(21):6205-15. doi: 10.1158/0008-5472.CAN-14-1716. Epub 2014 Sep 12.

PMID:
25217519
2.

A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk.

Vinayak S, Schwartz EJ, Jensen K, Lipson J, Alli E, McPherson L, Fernandez AM, Sharma VB, Staton A, Mills MA, Schackmann EA, Telli ML, Kardashian A, Ford JM, Kurian AW.

Breast Cancer Res Treat. 2013 Nov;142(2):389-98. doi: 10.1007/s10549-013-2739-z. Epub 2013 Oct 29.

PMID:
24166281
3.

Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol.

Alli E, Ford JM.

DNA Repair (Amst). 2012 May 1;11(5):522-4. doi: 10.1016/j.dnarep.2012.02.003. Epub 2012 Mar 14.

PMID:
22425348
4.

Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells.

Alli E, Sharma VB, Hartman AR, Lin PS, McPherson L, Ford JM.

BMC Pharmacol. 2011 Jul 19;11:7. doi: 10.1186/1471-2210-11-7.

5.

Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin.

Hastak K, Alli E, Ford JM.

Cancer Res. 2010 Oct 15;70(20):7970-80. doi: 10.1158/0008-5472.CAN-09-4521. Epub 2010 Aug 26.

6.

Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase.

Alli E, Sharma VB, Sunderesakumar P, Ford JM.

Cancer Res. 2009 Apr 15;69(8):3589-96. doi: 10.1158/0008-5472.CAN-08-4016. Epub 2009 Apr 7.

7.

Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells.

Alli E, Yang JM, Ford JM, Hait WN.

Mol Pharmacol. 2007 May;71(5):1233-40. Epub 2007 Feb 1.

8.

Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53.

Alli E, Yang JM, Hait WN.

Oncogene. 2007 Feb 15;26(7):1003-12. Epub 2006 Aug 14.

PMID:
16909102
9.

Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer.

Alli E, Bash-Babula J, Yang JM, Hait WN.

Cancer Res. 2002 Dec 1;62(23):6864-9.

10.

A Phase I/pilot study of sequential doxorubicin/vinorelbine: effects on p53 and microtubule-associated protein 4.

Bash-Babula J, Toppmeyer D, Labassi M, Reidy J, Orlick M, Senzon R, Alli E, Kearney T, August D, Shih W, Yang JM, Hait WN.

Clin Cancer Res. 2002 May;8(5):1057-64.

11.

[Ultrasonic examination of the status of the ovaries and endometrium after the treatment of tubal and peritoneal infertility].

Solomatina AA, Breusenko VG, Boginskaia LN, Alli EO, Shtyrov SV.

Akush Ginekol (Mosk). 1991 Oct;(10):41-4. Russian.

PMID:
1789324
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk